New Jer­sey biotech nets $50M+ BAR­DA con­tract for res­pi­ra­to­ry can­di­date

Ea­gle Phar­ma­ceu­ti­cals is keep­ing an eye on Enalare Ther­a­peu­tics’ lead res­pi­ra­to­ry can­di­date, and ap­par­ent­ly, so is the US gov­ern­ment.

The New Jer­sey-based biotech struck a deal with BAR­DA worth up to $50.3 mil­lion to de­vel­op the lead com­pound, dubbed ENA-001, the com­pa­ny an­nounced on Tues­day. The can­di­date is de­signed to sim­u­late breath­ing and is meant to be used in emer­gency cas­es when treat­ing drug over­dos­es or res­pi­ra­to­ry de­pres­sion post-surgery.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.